D. Boral Capital Upgrades Can Fite Biopharma to Buy, Announces $7 Price Target
Benzinga Newsdesk 5 months ago
NewsUpgradesPrice TargetAnalyst Ratings
D. Boral Capital analyst Jason Kolbert upgrades Can Fite Biopharma (AMEX:CANF) from Hold to Buy and announces $7 price target.
D. Boral Capital analyst Jason Kolbert upgrades Can Fite Biopharma (AMEX:CANF) from Hold to Buy and announces $7 price target.